AU2002236572A1 - Methods for detecting the efficacy of anticancer treatments - Google Patents
Methods for detecting the efficacy of anticancer treatmentsInfo
- Publication number
- AU2002236572A1 AU2002236572A1 AU2002236572A AU3657202A AU2002236572A1 AU 2002236572 A1 AU2002236572 A1 AU 2002236572A1 AU 2002236572 A AU2002236572 A AU 2002236572A AU 3657202 A AU3657202 A AU 3657202A AU 2002236572 A1 AU2002236572 A1 AU 2002236572A1
- Authority
- AU
- Australia
- Prior art keywords
- growth factor
- factor receptor
- receptor
- antibody
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24574500P | 2000-11-03 | 2000-11-03 | |
US60/245,745 | 2000-11-03 | ||
PCT/US2001/046937 WO2002039121A2 (en) | 2000-11-03 | 2001-11-02 | Methods for detecting the efficacy of anticancer treatments |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002236572A1 true AU2002236572A1 (en) | 2002-05-21 |
Family
ID=22927911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002236572A Abandoned AU2002236572A1 (en) | 2000-11-03 | 2001-11-02 | Methods for detecting the efficacy of anticancer treatments |
Country Status (6)
Country | Link |
---|---|
US (1) | US7344829B2 (de) |
EP (1) | EP1332368A2 (de) |
JP (1) | JP2004529315A (de) |
AU (1) | AU2002236572A1 (de) |
CA (1) | CA2427622A1 (de) |
WO (1) | WO2002039121A2 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1441736A2 (de) * | 2001-10-29 | 2004-08-04 | Novartis AG | Verwendung von 7h-pyrrolo[2,3-d]pyrimidinderivaten in der behandlung solider tumore |
KR101086533B1 (ko) * | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
AU2003286004A1 (en) * | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
WO2004041865A2 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
ES2466716T3 (es) * | 2002-11-08 | 2014-06-11 | Ablynx N.V. | Anticuerpos de un solo dominio estabilizados |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
SI2055786T1 (sl) * | 2002-11-27 | 2011-04-29 | Sugen Inc | Fosfospecifična PAK-protitelesa in diagnostični kompleti |
EP2251357A1 (de) * | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae schweren Ketten Antikörpern VHHS gegen Epidermal Growth Faktor Rezeptor (EGFR) und Ihre Verwendungen |
ATE514783T1 (de) | 2003-11-12 | 2011-07-15 | Schering Corp | Plasmidsystem zur expression mehrerer gene |
PE20050928A1 (es) * | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
MXPA06014015A (es) * | 2004-06-03 | 2007-02-08 | Hoffmann La Roche | Tratamiento con gemcitabina y un inhibidor del receptor del factor de crecimiento epidermico. |
RU2006146612A (ru) | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
MX2007006640A (es) * | 2004-12-03 | 2007-06-19 | Schering Corp | Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina. |
EP1879587A2 (de) * | 2005-04-15 | 2008-01-23 | Schering Corporation | Verfahren und zusammensetzungen zur behandlung oder vorbeugung von krebs |
AU2006259536A1 (en) * | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
GB2437250C (en) * | 2006-04-18 | 2012-08-15 | Iti Scotland Ltd | Method and system for monitoring the condition of livestock |
US20100291592A1 (en) * | 2006-04-20 | 2010-11-18 | Taro Semba | Novel marker for sensitivity against sulfonamide compound |
WO2008102495A1 (ja) * | 2007-02-22 | 2008-08-28 | Banyu Pharmaceutical Co., Ltd. | Mark4に作用する化合物の評価方法 |
US20090286263A1 (en) * | 2008-03-05 | 2009-11-19 | United States Army As Represented By The Secretary Of The Army | Skin tape stripping: a non-invasive diagnostic strategy for dermal exposure to cytotoxic compounds |
US8778331B2 (en) * | 2008-06-30 | 2014-07-15 | Medical Diagnostic Laboratories, Llc | Method of determining susceptibility of a tumor cell to a chemotherapeutic agent: novel use of herpes simplex virus |
WO2010030325A1 (en) * | 2008-09-09 | 2010-03-18 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for increasing efficacy of radioimmunotherapy of melanoma |
BR122018013284B1 (pt) | 2008-10-29 | 2022-03-03 | Ablynx N.V | Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab |
AU2009314311B2 (en) * | 2008-10-29 | 2013-01-10 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
US20110104719A1 (en) * | 2009-11-02 | 2011-05-05 | Aletta John M | Methylarginine detection in cells and tissues |
DK2706988T3 (da) | 2011-05-12 | 2020-01-20 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Liposomer omfattende polymer konjugerede lipider og relateret brug |
KR20210050326A (ko) * | 2019-10-28 | 2021-05-07 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68921918T2 (de) * | 1988-05-09 | 1995-09-07 | Univ Temple | Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten. |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
CA2106862A1 (en) * | 1991-03-27 | 1992-09-28 | Robert M. Lavker | Method of indentifying and modulating the activity of label retaining cells for diagnostic and therapeutic purposes |
CA2117913C (en) * | 1992-04-10 | 2006-05-09 | Richard J. Epstein | Activation-state-specific phosphoprotein immunodetection |
-
2001
- 2001-11-02 CA CA002427622A patent/CA2427622A1/en not_active Abandoned
- 2001-11-02 JP JP2002541395A patent/JP2004529315A/ja not_active Withdrawn
- 2001-11-02 AU AU2002236572A patent/AU2002236572A1/en not_active Abandoned
- 2001-11-02 EP EP01986107A patent/EP1332368A2/de not_active Withdrawn
- 2001-11-02 WO PCT/US2001/046937 patent/WO2002039121A2/en not_active Application Discontinuation
- 2001-11-02 US US10/010,763 patent/US7344829B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2004529315A (ja) | 2004-09-24 |
US7344829B2 (en) | 2008-03-18 |
US20020132275A1 (en) | 2002-09-19 |
CA2427622A1 (en) | 2002-05-16 |
WO2002039121A3 (en) | 2002-09-06 |
EP1332368A2 (de) | 2003-08-06 |
WO2002039121A2 (en) | 2002-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7344829B2 (en) | Methods for detecting the efficacy of anticancer treatments | |
ES2541925T3 (es) | Métodos y composiciones para el uso diagnóstico en pacientes de cáncer | |
Ikeda et al. | Prognostic significance of angiogenesis in human pancreatic cancer | |
Mukaida et al. | Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer | |
AU2014312079B2 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
McKeever et al. | A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters | |
US20080226646A1 (en) | Use of biomolecular targets in the treatment and visualization of tumors | |
McKeever et al. | MIB-1 proliferation index predicts survival among patients with grade II astrocytoma | |
Yardley et al. | Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a Sarah Cannon Research Institute phase II trial | |
WO2005094332A2 (en) | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer | |
Yang et al. | Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer | |
KR101928618B1 (ko) | Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법 | |
Hatori et al. | Midkine expression in human periapical granulomas | |
Häggström et al. | Castration‐induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer | |
KR20200106921A (ko) | 암을 치료하기 위한 방법 및 조합 요법 | |
JP7206203B2 (ja) | がんの重症度を評価するためのtim-3 | |
Huang et al. | Cluster of differentiation 24 expression is an independent prognostic factor of adverse outcome in cervical carcinoma | |
Zhang et al. | Gastrointestinal (Non-colorectal) Cancer | |
WO2023083863A1 (en) | Method for monitoring the response to neoadjuvant therapy for breast cancer | |
Ahmed Shameem et al. | Expression of proliferating cell nuclear antigen and deoxyribonucleic acid value in renal cell carcinoma: correlation with different histopathological parameters and patient survival | |
Stål et al. | Overexpression of c-erbB-2 protein and locoregional recurrence in node-positive breast cancer | |
KR20230075765A (ko) | 동시항암방사선치료를 받은 비소세포성 폐암 환자의 방사선 폐렴 중증도의 예측 방법 | |
CN114480634A (zh) | 半乳糖凝集素-1作为一种生物标志物在诊断肿瘤耐药中的应用 | |
KR20220149336A (ko) | 부인암 pdx 모델에 대한 성공 예측 방법 | |
US20150355185A1 (en) | Using galectin-binding carbohydrates as predictors of melanoma progression and metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |